Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Laura Hutchins

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Med, College of Medicine
DivisionInternal Med Hem-Onc
Address10-57 Cancer Institute
4301 W. Markham
Mail Slot # 508
Little Rock AR 72205
Phone501-526-6990 x8032
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Laura F. Hutchins is a hematologist and medical oncologist at the Winthrop P. Rockefeller Cancer Institute and Professor of Medicine in the Department of Internal Mediicne, Division of Hematology Oncolology at the University of Arkansas for Medical Sciences (UAMS). Dr. Hutchins received her medical degree from UAMS and continued there to complete her internship, residency and fellowship in hematology/oncology. She is board certified in Internal Medicine, Hematology, Oncology and Hospice and Palliative Medicine. Dr. Hutchins is a member of the American College of Physicians, American Society of Hematology, American Society of Clinical Oncology (ASCO), American Association of Cancer Education and the American Medical Association. She serves on several national committees for ASCO and the Southwest Oncology Group. Dr. Hutchins is the Director of Clinical Research for the Winthrop P. Rockefeller Cancer Institute and holds the Virginia Clinton Kelly Endowed Chair for Clinical Breast Cancer Research.


    Collapse Research 
    Collapse research activities and funding
    UL1TR003107     (JAMES, LAURA P)Jul 1, 2019 - Jun 30, 2024
    NIH
    Expanding Translational Research in Arkansas
    Role: Co-Investigator
    R21CA230059     (GALANZHA, EKATERINA I.)Sep 11, 2018 - Aug 31, 2020
    NIH
    Lymph liquid biopsy in cancer
    Role: Co-Investigator
    U54TR001629     (JAMES, LAURA P)Sep 26, 2017 - Aug 31, 2019
    NIH
    Expanding Translational Research in Arkansas
    Role: Co-Investigator
    SWOG 1404     (HUTCHINS, LAURA)Oct 7, 2016
    Southwest Oncology Group-Clinical Trial Initiative
    SWOG 1404
    Role: Principal Investigator
    SWOG1404     (HUTCHINS, LAURA)Oct 7, 2016
    Southwest Oncology Group-Clinical Trial Initiative
    SWOG 1404
    Role: Principal Investigator
    U24OD024957     (OUNPRASEUTH, SONGTHIP T.;SNOWDEN, JESSICA)Sep 23, 2016 - Aug 31, 2025
    NIH
    Data Coordinating and Operations Center for the ECHO IDeA States Pediatric Clinical Trials Network
    Role: Co-Investigator
    U24HD090912     (HOBBS, CHARLOTTE A)Sep 21, 2016 - Sep 22, 2016
    NIH
    Data Coordinating and Operations Center (DCOC) for the IDeA States Pediatric Clinical Trials Network
    Role: Co-Investigator
    ABT     (HUTCHINS, LAURA)Jul 31, 2015
    AbbVie Inc
    A Phase III Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel with or without the PARP Inhibitor Verliparib (ABT-888) in Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
    Role: Principal Investigator
    ABT-888     (HUTCHINS, LAURA)Jul 31, 2015
    AbbVie Inc
    A Phase III Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel with or without the PARP Inhibitor Verliparib (ABT-888) in Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
    Role: Principal Investigator
    SWOG 1320     (GOVINDARAJAN, RANGASWAMY)Apr 24, 2015
    NIH/Nat. Cancer Institute - Pass Through: Oregon Health & Science University
    No FP attached
    Role: Principal Investigator
    CDX     (HUTCHINS, LAURA)Nov 17, 2014
    Celldex Therapuetics
    CDX-11
    Role: Principal Investigator
    CDX-011     (HUTCHINS, LAURA)Nov 17, 2014
    Celldex Therapuetics
    CDX-11
    Role: Principal Investigator
    SWOG 1222     (HUTCHINS, LAURA F)Oct 31, 2014
    Hope Foundation - Pass Through: SouthWest Oncology Group
    No FP attached
    Role: Principal Investigator
    SWOG1222     (HUTCHINS, LAURA)Oct 31, 2014
    Hope Foundation - Pass Through: SouthWest Oncology Group
    SWOG 1222
    Role: Principal Investigator
    SWOG 1115     (HUTCHINS, LAURA)May 7, 2013
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    S1115, Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) VS mFOLFOX in Patients with Metastatic Pan
    Role: Principal Investigator
    SWOG1115     (HUTCHINS, LAURA)May 7, 2013
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    S1115, Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) VS mFOLFOX in Patients with Metastatic Pan
    Role: Principal Investigator
    POL     (HUTCHINS, LAURA)Oct 23, 2012
    Polynoma LLC
    A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients wi
    Role: Principal Investigator
    POL-103A     (HUTCHINS, LAURA)Oct 23, 2012
    Polynoma LLC
    A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients wi
    Role: Principal Investigator
    S1105     (HUTCHINS, LAURA F)Oct 9, 2012
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    S1105, Randomized Trial of Text-Messaging Intervention to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women with Early Sta
    Role: Principal Investigator
    M12     (HUTCHINS, LAURA)Aug 7, 2012
    Abbott, Inc.
    “A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplat
    Role: Principal Investigator
    M12-895     (HUTCHINS, LAURA)Aug 7, 2012
    Abbott, Inc.
    “A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplat
    Role: Principal Investigator
    E2607     (HUTCHINS, LAURA)Jun 26, 2012
    NIH/Nat. Cancer Institute - Pass Through: Eastern Cooperative Oncology Group
    CTSU E2607 A Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melan
    Role: Principal Investigator
    S1201     (HUTCHINS, LAURA)Jun 6, 2012
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    S1201, A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Ad
    Role: Principal Investigator
    U01CA114650     (HENRY-TILLMAN, RONDA S)May 1, 2012 - Apr 30, 2013
    NIH/Nat. Cancer Institute - Pass Through: University of Maryland
    Understanding Esophageal Cancer in African American Patients
    Role: Co-Investigator
    SWOG 0927     (HUTCHINS, LAURA F)Apr 25, 2012
    NIH/Nat. Cancer Institute - Pass Through: Southwest Oncology Group-Clinical Trial Initiative
    SWOG 0927, A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Co
    Role: Principal Investigator
    SWOG0927     (HUTCHINS, LAURA)Apr 25, 2012
    NIH/Nat. Cancer Institute - Pass Through: Southwest Oncology Group-Clinical Trial Initiative
    SWOG 0927, A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffne
    Role: Principal Investigator
    SWOG 0820     (HUTCHINS, LAURA)Apr 10, 2012
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 0820 A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorect
    Role: Principal Investigator
    SWOG0820     (HUTCHINS, LAURA F)Apr 10, 2012
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 0820 A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorect
    Role: Principal Investigator
    CA032102     (HUTCHINS, LAURA)Feb 28, 2012
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG #1014, Abiraterone Acetate Treatment for Prostate Cancer Patients with a PSA of More Than Four Following Initial Androgen Deprivation Therapy, Ph
    Role: Principal Investigator
    SK2302024A     (HUTCHINS, LAURA F)Feb 24, 2012 - Feb 23, 2022
    GlaxoSmithKline
    Study of GSK2302024A Antigen-Specific Cancer Immunotherapeutic combined with standard neoadjuvant treatment in patients with WT1-positive primary inva
    Role: Principal Investigator
    SWOG 0933     (HUTCHINS, LAURA)Oct 18, 2011
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 0933, Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
    Role: Principal Investigator
    SWOG0933     (HUTCHINS, LAURA)Oct 18, 2011
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 0933, Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
    Role: Principal Investigator
    SWOG 0816     (HUTCHINS, LAURA)Jul 19, 2011
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 0816, A Phase II Trial of Response Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging
    Role: Principal Investigator
    SWOG0816     (HUTCHINS, LAURA F)Jul 19, 2011
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 0816, A Phase II Trial of Response Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging
    Role: Principal Investigator
    S0931     (HUTCHINS, LAURA)Jul 5, 2011
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 0931, EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study
    Role: Principal Investigator
    Oncolytic Vaccine     (HUTCHINS, LAURA)Apr 29, 2011
    BioVex, Inc
    A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment with OncoVEXGM CSF Compared to Subcutaneously Administered GM-CSF
    Role: Principal Investigator
    OncolyticVaccine     (HUTCHINS, LAURA)Apr 29, 2011
    BioVex, Inc
    A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment with OncoVEXGM CSF Compared to Subcutaneously Administered GM-CSF
    Role: Principal Investigator
    SWOG 1005     (HUTCHINS, LAURA F)Apr 26, 2011
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 1005, “A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer”
    Role: Principal Investigator
    SWOG1005     (HUTCHINS, LAURA F)Apr 26, 2011
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 1005, “A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer”
    Role: Principal Investigator
    S0925     (HUTCHINS, LAURA F)Apr 19, 2011
    NIH/Nat. Cancer Institute - Pass Through: Southwest Oncology Group-Clinical Trial Initiative
    SWOG 0925, A Randomized Phase II Study of Androgen Deprivation Combined with IMC-A12 Versus Androgen Deprivation Alone for Patients with New Hormone-S
    Role: Principal Investigator
    SWOG 0702     (HUTCHINS, LAURA F)Mar 8, 2011
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 0702, A PROSPECTIVE OBSERVATIONAL MULTICENTER COHORT STUDY TO ASSESS THE INCIDENCE OF OSTEONECROSIS OF THE JAW (ONJ) IN CANCER PATIENTS WITH BONE
    Role: Principal Investigator
    SWOG0702     (HUTCHINS, LAURA)Mar 8, 2011
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 0702, A PROSPECTIVE OBSERVATIONAL MULTICENTER COHORT STUDY TO ASSESS THE INCIDENCE OF OSTEONECROSIS OF THE JAW (ONJ) IN CANCER PATIENTS WITH BONE
    Role: Principal Investigator
    SWOG 0910     (HUTCHINS, LAURA F)Feb 1, 2011
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 0910, A Phase II Study of Epratuzumab (NSC-716711) in Combination with Cytarabine and Clofarabine for Patients with Relapsed or Refractory Ph-Neg
    Role: Principal Investigator
    SWOG0910     (HUTCHINS, LAURA F)Feb 1, 2011
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 0910, A Phase II Study of Epratuzumab (NSC-716711) in Combination with Cytarabine and Clofarabine for Patients with Relapsed or Refractory Ph-Neg
    Role: Principal Investigator
    SWOG 0919     (HUTCHINS, LAURA)Jan 25, 2011
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    - SWOG 0919 A PHASE II STUDY OF IDARUBICIN AND ARA-C IN COMBINATION WITH PRAVASTATIN FOR RELAPSED ACUTE MYELOGENOUS LEUKEMIA (AML)
    Role: Principal Investigator
    SWOG0919     (HUTCHINS, LAURA)Jan 25, 2011
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    - SWOG 0919 A PHASE II STUDY OF IDARUBICIN AND ARA-C IN COMBINATION WITH PRAVASTATIN FOR RELAPSED ACUTE MYELOGENOUS LEUKEMIA (AML)
    Role: Principal Investigator
    SWOG 0230     (HUTCHINS, LAURA)Oct 25, 2010
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 0230, Phase III Trial Of LHRH Analog Administration During Chemotherapy To Reduce Ovarian Failure Following Chemotherapy In Early Stage, Hormone-
    Role: Principal Investigator
    SWOG0230     (HUTCHINS, LAURA F)Oct 25, 2010
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 0230, Phase III Trial Of LHRH Analog Administration During Chemotherapy To Reduce Ovarian Failure Following Chemotherapy In Early Stage, Hormone-
    Role: Principal Investigator
    SWOG 0622     (HUTCHINS, LAURA)Sep 28, 2010
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 0622 Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Metastatic Breast Cancer
    Role: Principal Investigator
    SWOG0622     (HUTCHINS, LAURA F)Sep 28, 2010
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 0622 Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Metastatic Breast Cancer
    Role: Principal Investigator
    S0802     (HUTCHINS, LAURA F)Sep 21, 2010
    NIH/Nat. Cancer Institute - Pass Through: Southwest Oncology Group-Clinical Trial Initiative
    SWOG 0802, A Randomized Phase II Trial Of Weekly Topotecan With And Without AVE0005 (Aflibercept; NSC-724770) In Patients With Platinum Treated Extens
    Role: Principal Investigator
    SWOG 0800     (HUTCHINS, LAURA F)Aug 10, 2010
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 0800, A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Eith
    Role: Principal Investigator
    SWOG0800     (HUTCHINS, LAURA)Aug 10, 2010
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    SWOG 0800, A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Eith
    Role: Principal Investigator
    S0826     (HUTCHINS, LAURA)Aug 3, 2010 - Aug 2, 2020
    NIH/Nat. Cancer Institute - Pass Through: Southwest Oncology Group-Clinical Trial Initiative
    SWOG 0826, A PHASE II TRIAL OF SCH 727965 (NSC 747135) IN PATIENTS WITH STAGE IV MELANOMA
    Role: Principal Investigator
    SWOG 0709     (HUTCHINS, LAURA)Aug 3, 2010
    NIH/Nat. Cancer Institute - Pass Through: Southwest Oncology Group-Clinical Trial Initiative
    CFDA # 93.395SWOG 0709,Federal funding- A PHASE II SELECTION DESIGN OF PHARMACODYNAMIC SEPARATION OF CARBOPLATIN/PACLITAXEL/ERLOTINIB OR ERLOTINIB ALO
    Role: Principal Investigator
    SWOG0709     (HUTCHINS, LAURA F)Aug 3, 2010
    NIH/Nat. Cancer Institute - Pass Through: Southwest Oncology Group-Clinical Trial Initiative
    CFDA # 93.395SWOG 0709,Federal funding- A PHASE II SELECTION DESIGN OF PHARMACODYNAMIC SEPARATION OF CARBOPLATIN/PACLITAXEL/ERLOTINIB OR ERLOTINIB ALO
    Role: Principal Investigator
    CA033     (HUTCHINS, LAURA F)Aug 2, 2010
    Abraxis BioScience, LLC
    CA033 entitled: “An Open-Label, Multicenter, Phase III Trial of ABI-007 vs. Dacarbazine in Previously Untreated Patients with Metastatic Malignant Mel
    Role: Principal Investigator
    HHSN263999900046I     (HUTCHINS, LAURA F)Jun 15, 2010 - Apr 14, 2011
    NIH/Nat. Cancer Institute - Pass Through: Booz Allen Hamilton
    caBIG CTMS Workspace
    Role: Principal Investigator
    SWOG 0819     (HUTCHINS, LAURA F)May 25, 2010
    NIH/Nat. Cancer Institute - Pass Through: Southwest Oncology Group-Clinical Trial Initiative
    SWOG 0819, A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel Or Carb
    Role: Principal Investigator
    SWOG0819     (HUTCHINS, LAURA)May 25, 2010
    NIH/Nat. Cancer Institute - Pass Through: Southwest Oncology Group-Clinical Trial Initiative
    SWOG 0819, A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel Or Carboplatin/Paclitaxel/Bevacizumab With Or Without Concurrent Cetuximab i
    Role: Principal Investigator
    H8K-MC-JZAO     (HUTCHINS, LAURA)Apr 5, 2010
    Lilly USA, LLC
    Protocol H8K-MC-JZAO A Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28 Day Cycle vs. Paclitaxel as Seco
    Role: Principal Investigator
    OncoVEXGM-CSF     (HUTCHINS, LAURA F)Nov 19, 2009
    BioVex, Inc
    ”A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment with OncoVEXGM-CSF Compared to Subcutaneously Administered GM-CS
    Role: Principal Investigator
    MAGE A-3     (HUTCHINS, LAURA F)Aug 26, 2009 - Apr 24, 2014
    GlaxoSmithKline
    A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with M
    Role: Principal Investigator
    MAGEA-3     (HUTCHINS, LAURA)Aug 26, 2009 - Apr 24, 2014
    GlaxoSmithKline
    A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with M
    Role: Principal Investigator
    R01EB009230     (ZHAROV, VLADIMIR P)Jul 15, 2009 - Apr 30, 2014
    NIH
    Multifunctional nanotubes for in vivo detecting/purging circulating cancer cells
    Role: Co-Investigator
    A3671024     (HUTCHINS, LAURA)Aug 21, 2008 - Aug 21, 2013
    MedImmune, LLC
    A Rollover Protocol for Patients who Received CP-675 206 in Other Protocols
    Role: Principal Investigator
    R01CA131164     (SUEN, JAMES)Dec 1, 2007 - Mar 31, 2021
    NIH
    In vivo real time detection of circulating melanoma cells
    Role: Co-Investigator
    CA 184-045     (HUTCHINS, LAURA F)Oct 16, 2007 - Jun 17, 2014
    Bristol-Meyers Squibb
    A Multi-center Treatment Protocol for Compassionate Use of Ipilimumab (BMS-734016) Monotherapy in Subjects with Unresectable Stage III or Stage IV mel
    Role: Principal Investigator
    CA184     (HUTCHINS, LAURA)Oct 16, 2007 - Jun 17, 2014
    Bristol-Meyers Squibb
    A Multi-center Treatment Protocol for Compassionate Use of Ipilimumab (BMS-734016) Monotherapy in Subjects with Unresectable Stage III or Stage IV mel
    Role: Principal Investigator
    U10CA32102     (HUTCHINS, LAURA)Jan 1, 2007 - Dec 31, 2007
    NIH/Nat. Cancer Institute - Pass Through: University of Michigan
    SWOG High Accural Award
    Role: Principal Investigator
    CA184-008     (HUTCHINS, LAURA F)Nov 17, 2006 - Nov 17, 2009
    Bristol-Meyers Squibb
    Protocol CA184-008 A Multi-center Single Arm Phase II Study of MDX-010 (BMS 734016) Monotherapy in Patients with Previously Treated Unresectable Stag
    Role: Principal Investigator
    Pfizer A3671009     (HUTCHINS, LAURA)Aug 8, 2006 - Aug 8, 2009
    Pfizer, Inc.
    UARK 2005-33: Phase 3, open label, randomized comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melano
    Role: Principal Investigator
    PfizerA3671009     (HUTCHINS, LAURA F)Aug 8, 2006 - Aug 8, 2009
    Pfizer, Inc.
    UARK 2005-33: Phase 3, open label, randomized comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melano
    Role: Principal Investigator
    Eisai E7389-G000-211     (HUTCHINS, LAURA)Jul 18, 2006 - Jul 1, 2010
    Eisai
    A Phase II Open Label Single-Arm Study of E7389 in Patients with Locally Advanced or Metastatic Breast Cancer, Previously Treated with Anthracycline,
    Role: Principal Investigator
    EisaiE7389-G000     (HUTCHINS, LAURA F)Jul 18, 2006 - Jul 1, 2010
    Eisai
    A Phase II Open Label Single-Arm Study of E7389 in Patients with Locally Advanced or Metastatic Breast Cancer, Previously Treated with Anthracycline,
    Role: Principal Investigator
    W81XWH-06-1-0542     (KIEBER-EMMONS, THOMAS)Apr 24, 2006 - Nov 23, 2013
    US Department of the Army
    Vaccination of High-Risk Breast Cancer patients with Carbohydrate Mimicking Peptides
    Role: Co-Investigator
    W81XWH-06-1-0542 (BC050157)     (KIEBER-EMMONS, THOMAS)Apr 24, 2006 - May 24, 2011
    US Department of the Army
    Vaccination of High-Risk Breast Cancer patients with Carbohydrate Mimicking Peptides
    Role: Co-Investigator
    155-CL     (HUTCHINS, LAURA F)Mar 29, 2006 - Nov 30, 2007
    Astellas Pharma US, Inc.
    A Phase II, Multicenter, Open Label Study of YM155 in Subjects with Unresectable Stage III or Metastatic (Stage IV) Melanoma as First-Line Therapy
    Role: Principal Investigator
    155-CL-008     (HUTCHINS, LAURA F)Mar 29, 2006 - Nov 30, 2007
    Astellas Pharma US, Inc.
    A Phase II, Multicenter, Open Label Study of YM155 in Subjects with Unresectable Stage III or Metastatic (Stage IV) Melanoma as First-Line Therapy
    Role: Principal Investigator
    1435     (HUTCHINS, LAURA F)Mar 7, 2006 - Mar 6, 2009
    NIH/Nat. Cancer Institute - Pass Through: Booz Allen Hamilton
    caBIG C3d technical proposal
    Role: Principal Investigator
    1435-04-04-CT-73980 supplement     (HUTCHINS, LAURA)Mar 7, 2006 - Mar 6, 2009
    NIH/Nat. Cancer Institute - Pass Through: Booz Allen Hamilton
    caBIG C3d technical proposal
    Role: Principal Investigator
    88017CBS17     (HUTCHINS, LAURA F)Mar 7, 2006 - Mar 6, 2009
    NIH/Nat. Cancer Institute - Pass Through: Booz Allen Hamilton
    caBIG C3d technical proposal
    Role: Principal Investigator
    CP     (HUTCHINS, LAURA)Mar 1, 2006 - Mar 1, 2009
    Pfizer, Inc.
    Phase 2 Open-Label, Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability and Pharmakokinetics of CP-675-206 in pts w/ Adv Refractory /
    Role: Principal Investigator
    CP-675-206 CSA     (HUTCHINS, LAURA)Mar 1, 2006 - Mar 1, 2009
    Pfizer, Inc.
    Phase 2 Open-Label, Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability and Pharmakokinetics of CP-675-206 in pts w/ Adv Refractory /
    Role: Principal Investigator
    SWOG 0316 CTA     (HUTCHINS, LAURA F)Feb 8, 2005 - Sep 30, 2007
    Breast Cancer Research Foundation - Pass Through: University of Washington
    SWOG 0316, Barriers to Accrual to Clinical Trials in Older (>65 Years) Cancer Patient
    Role: Principal Investigator
    SWOG0316CTA     (HUTCHINS, LAURA)Feb 8, 2005 - Sep 30, 2007
    Breast Cancer Research Foundation - Pass Through: University of Washington
    SWOG 0316, Barriers to Accrual to Clinical Trials in Older (>65 Years) Cancer Patient
    Role: Principal Investigator
    PRN 28766 P03267 MCTAA     (HUTCHINS, LAURA F)Feb 8, 2005 - Feb 8, 2007
    Schering-Plough Research Institute
    UARK 2004-26 (P03267-10) Extended Schedule, Escalated Dose Temozolomide versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III St
    Role: Principal Investigator
    PRN28766P03267MCTAA     (HUTCHINS, LAURA F)Feb 8, 2005 - Feb 8, 2007
    Schering-Plough Research Institute
    UARK 2004-26 (P03267-10) Extended Schedule, Escalated Dose Temozolomide versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III St
    Role: Principal Investigator
    2004     (HUTCHINS, LAURA F)Dec 22, 2004 - Dec 22, 2005
    Point Therapeutics, Inc
    UARK 2004-46 (PTH303): Open Label Phase 2 Trial of PT-100 in Patients with Metastatic Melanoma
    Role: Principal Investigator
    2004-46 PTH303 CTA     (HUTCHINS, LAURA)Dec 22, 2004 - Dec 22, 2005
    Point Therapeutics, Inc
    UARK 2004-46 (PTH303): Open Label Phase 2 Trial of PT-100 in Patients with Metastatic Melanoma
    Role: Principal Investigator
    UARK 2004-20 STA-4783 CTA     (HUTCHINS, LAURA F)Sep 14, 2004 - Aug 7, 2006
    PPD Development, LP - Pass Through: PPD Development, LP
    UARK 2004-20: A Two-Stage Trial of STA-4783 in Combination with Weekly Paclitaxel for Treatment of Patients with Metastatic Melanoma
    Role: Principal Investigator
    UARK2004     (HUTCHINS, LAURA F)Sep 14, 2004 - Aug 7, 2006
    PPD Development, LP - Pass Through: PPD Development, LP
    UARK 2004-20: A Two-Stage Trial of STA-4783 in Combination with Weekly Paclitaxel for Treatment of Patients with Metastatic Melanoma
    Role: Principal Investigator
    RSR13 RT-016 CTA     (HUTCHINS, LAURA F)Sep 1, 2004 - Sep 1, 2008
    Allos Therapeutics, Inc.
    RSR13 RT-016: A Phase 3 Randomized, Open-Label Comparative Study of Standard Whole Brain Radiation Therapy With Supplemental Oxygen, With or Without C
    Role: Principal Investigator
    RSR13RT     (HUTCHINS, LAURA)Sep 1, 2004 - Sep 1, 2008
    Allos Therapeutics, Inc.
    RSR13 RT-016: A Phase 3 Randomized, Open-Label Comparative Study of Standard Whole Brain Radiation Therapy With Supplemental Oxygen, With or Without C
    Role: Principal Investigator
    UARK 2002-14     (HUTCHINS, LAURA F)Oct 1, 2002 - Oct 1, 2004
    Chugai Biopharmaceuticals, Inc.
    UARK 2002-14, CAL-03: A Phase I-II, 24 Week, Mulitcenter, Double-Blind, Randomized, Dose-Ranging Study to Evaluate the Safety and Efficacy of a Humani
    Role: Principal Investigator
    UARK 2002-01     (HUTCHINS, LAURA F)Jul 1, 2002 - Jul 1, 2004
    CancerVax Corporation
    UARK 2002-01 A Phase III Randomized Double-Blind Pivotal Trial of Immuntherapy with BCG plus a Polyvalent Melanoma Vaccine, CancerVax Vaccine, versus
    Role: Principal Investigator
    UARK 2002-02     (HUTCHINS, LAURA F)Jul 1, 2002 - Jul 1, 2004
    CancerVax Corporation
    UARK 2002-02, A Phase III Randomized Double-Blind Trial of Immunotherapy with a Polyvalent Melanoma Vaccine, CancerVax Vaccine, plus BCG versus Placeb
    Role: Principal Investigator
    UARK 2002-02 Amend 1     (HUTCHINS, LAURA F)Jul 1, 2002 - Jul 1, 2004
    CancerVax Corporation
    UARK 2002-02, A Phase III Randomized Double-Blind Trial of Immunotherapy with a Polyvalent Melanoma Vaccine, CancerVax Vaccine, plus BCG versus Placeb
    Role: Principal Investigator
    UARK 2000-58     (HUTCHINS, LAURA)Apr 1, 2001 - Apr 1, 2004
    Genta, Inc.
    UARK 2000-58, Randomized Study of Dacarbazine vs. Dacarbazine Plus G3139 (Bcl-2 Antisense Oligonucleotide) in Patients with Advanced Melanoma
    Role: Principal Investigator
    UARK2000     (HUTCHINS, LAURA F)Apr 1, 2001 - Apr 1, 2004
    Genta, Inc.
    UARK 2000-58, Randomized Study of Dacarbazine vs. Dacarbazine Plus G3139 (Bcl-2 Antisense Oligonucleotide) in Patients with Advanced Melanoma
    Role: Principal Investigator
    NOV CGOP4244604037     (HUTCHINS, LAURA)Jul 15, 1999
    NOVARTIS Pharmaceuticals Corporation
    NOV CGOP4244604037
    Role: Principal Investigator
    NOVCGOP4244604037     (HUTCHINS, LAURA F)Jul 15, 1999
    NOVARTIS Pharmaceuticals Corporation
    NOV CGOP4244604037
    Role: Principal Investigator
    R25CA049425     (KELLY JR, THOMAS J)Sep 30, 1989 - Jun 30, 2006
    NIH/Nat. Cancer Institute
    Student Partners in Cancer Research and Education
    Role: Co-Principal Investigator
    U10CA037981     (HUTCHINS, LAURA F)Jul 15, 1984 - Dec 31, 2003
    NIH
    SOUTHWEST ONCOLOGY GROUP
    Role: Principal Investigator
    UARK 2002-4     (HUTCHINS, LAURA F)Apr 30, 2010
    Chugai Biopharmaceuticals, Inc.
    UARK 2002-4
    Role: Principal Investigator
    UARK2002-4     (HUTCHINS, LAURA F)Apr 30, 2010
    Chugai Biopharmaceuticals, Inc.
    UARK 2002-4
    Role: Principal Investigator
    UARK 2003-03     (HUTCHINS, LAURA F)Mar 31, 2010
    Genta, Inc.
    UARK 2003-03
    Role: Principal Investigator
    UARK2003     (HUTCHINS, LAURA)Mar 31, 2010
    Genta, Inc.
    UARK 2003-03
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Li C, Malapati SJ, Guire JT, Hutchins LF. Consistency Between State's Cancer Registry and All-Payer Claims Database in Documented Radiation Therapy Among Patients Who Received Breast Conservative Surgery. JCO Clin Cancer Inform. 2023 01; 7:e2200099. PMID: 36724402.
      View in: PubMed
    2. Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021 05; 9(5). PMID: 33963015.
      View in: PubMed
    3. Gerson SL, Shaw K, Harrison LB, Holcombe RF, Hutchins L, Lee CB, Loehrer PJ, Mulkerin D, Purcell WT, Teston L, Weiner LM, Weiner GJ. Status of Cancer Care at Network Sites of the Nation's Academic Cancer Centers. J Natl Compr Canc Netw. 2021 03 11; 19(6):726-732. PMID: 33706258.
      View in: PubMed
    4. Hernandez Puente CV, Hsu PC, Rogers LJ, Jousheghany F, Siegel E, Kadlubar SA, Beck JT, Makhoul I, Hutchins LF, Kieber-Emmons T, Monzavi-Karbassi B. Association of DNA-Methylation Profiles With Immune Responses Elicited in Breast Cancer Patients Immunized With a Carbohydrate-Mimicking Peptide: A Pilot Study. Front Oncol. 2020; 10:879. PMID: 32582547.
      View in: PubMed
    5. Joshi K, Atwal D, Ravilla R, Pandey Y, Yarlagadda N, Kakadia S, Makhoul I, Hutchins L, Mahmoud F. Immunotherapy Outcomes in Advanced Melanoma in Relation to Age. Perm J. 2020; 24. PMID: 32097116.
      View in: PubMed
    6. Tarhini AA, Lee SJ, Hodi FS, Rao UNM, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol. 2020 02 20; 38(6):567-575. PMID: 31880964.
      View in: PubMed
    7. Galanzha EI, Menyaev YA, Yadem AC, Sarimollaoglu M, Juratli MA, Nedosekin DA, Foster SR, Jamshidi-Parsian A, Siegel ER, Makhoul I, Hutchins LF, Suen JY, Zharov VP. In vivo liquid biopsy using Cytophone platform for photoacoustic detection of circulating tumor cells in patients with melanoma. Sci Transl Med. 2019 06 12; 11(496). PMID: 31189720.
      View in: PubMed
    8. Larsen V, Barlow WE, Yang JJ, Zhu Q, Liu S, Kwan ML, Ergas IJ, Roh JM, Hutchins LF, Kadlubar SA, Albain KS, Rae JM, Yeh IT, Ravdin PM, Martino S, Lyss AP, Osborne CK, Hortobagyi GN, Kushi LH, Hayes DF, Ambrosone CB, Yao S. Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study. Clin Breast Cancer. 2019 08; 19(4):225-235.e2. PMID: 30928413.
      View in: PubMed
    9. Sherman AC, Simonton-Atchley S, Mikeal CW, Anderson KM, Arnaoutakis K, Hutchins LF, Makhoul I, Mahmoud F, Milojkovic N, Harrington SE, Suen JY. Cancer patient perspectives regarding preparedness for end-of-life care: A qualitative study. J Psychosoc Oncol. 2018 Jul-Aug; 36(4):454-469. PMID: 29863447.
      View in: PubMed
    10. Campbell K, Kumarapeli AR, Gokden N, Cox RM, Hutchins L, Gardner JM. Metastatic melanoma with dedifferentiation and extensive rhabdomyosarcomatous heterologous component. J Cutan Pathol. 2018 May; 45(5):360-364. PMID: 29405341.
      View in: PubMed
    11. Johann DJ, Steliga M, Shin IJ, Yoon D, Arnaoutakis K, Hutchins L, Liu M, Liem J, Walker K, Pereira A, Yang M, Jeffus SK, Peterson E, Xu J. Liquid biopsy and its role in an advanced clinical trial for lung cancer. Exp Biol Med (Maywood). 2018 02; 243(3):262-271. PMID: 29405770.
      View in: PubMed
    12. Makhoul I, Motwani P, Schafer L, Arnaoutakis K, Mahmoud F, Safar M, Graves D, Mehta P, Govindarajan R, Hutchins L, Thrush C. Integrating Collaborative Learning and Competition in a Hematology/Oncology Training Program. J Cancer Educ. 2018 02; 33(1):186-192. PMID: 27516202.
      View in: PubMed
    13. Chesney J, Awasthi S, Curti B, Hutchins L, Linette G, Triozzi P, Tan MCB, Brown RE, Nemunaitis J, Whitman E, Windham C, Lutzky J, Downey GF, Batty N, Amatruda T. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma. Melanoma Res. 2018 02; 28(1):44-51. PMID: 29176501.
      View in: PubMed
    14. Hutchins LF, Makhoul I, Emanuel PD, Pennisi A, Siegel ER, Jousheghany F, Guo X, Pashov AD, Monzavi-Karbassi B, Kieber-Emmons T. Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects. Oncotarget. 2017 Nov 17; 8(58):99161-99178. PMID: 29228761.
      View in: PubMed
    15. Firwana B, Avaritt N, Shields B, Ravilla R, Makhoul I, Hutchins L, Tackett AJ, Mahmoud F. Do checkpoint inhibitors rely on gut microbiota to fight cancer? J Oncol Pharm Pract. 2018 Sep; 24(6):468-472. PMID: 28625074.
      View in: PubMed
    16. Kaur V, Swami A, Alapat D, Abdallah AO, Motwani P, Hutchins LF, Jethava Y. Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years. Hematology. 2018 Jan; 23(1):17-24. PMID: 28574302.
      View in: PubMed
    17. Mahmoud F, Shields B, Makhoul I, Avaritt N, Wong HK, Hutchins LF, Shalin S, Tackett AJ. Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack. Cancer Biol Ther. 2017 Jul 03; 18(7):451-469. PMID: 28513269.
      View in: PubMed
    18. Kieber-Emmons T, Monzavi-Karbassi B, Hutchins LF, Pennisi A, Makhoul I. Harnessing benefit from targeting tumor associated carbohydrate antigens. Hum Vaccin Immunother. 2017 02; 13(2):323-331. PMID: 27929800.
      View in: PubMed
    19. Makhoul I, Todorova VK, Siegel ER, Erickson SW, Dhakal I, Raj VR, Lee JY, Orloff MS, Griffin RJ, Henry-Tillman RS, Klimberg S, Hutchins LF, Kadlubar SA. Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients. PLoS One. 2017; 12(1):e0168550. PMID: 28045923.
      View in: PubMed
    20. Kieber-Emmons T, Makhoul I, Pennisi A, Siegel ER, Emanuel PD, Monzavi-Karbassi B, Steplewski Z, Beck JT, Hutchins LF. Managing Expectations in the Transition to Proof of Concept Studies. Rev Recent Clin Trials. 2017; 12(2):111-123. PMID: 28325150.
      View in: PubMed
    21. Firwana B, Ravilla R, Raval M, Hutchins L, Mahmoud F. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract. 2017 Dec; 23(8):620-624. PMID: 27590328.
      View in: PubMed
    22. Pennisi A, Kieber-Emmons T, Makhoul I, Hutchins L. Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer. Breast Cancer (Auckl). 2016; 10:103-6. PMID: 27478380.
      View in: PubMed
    23. Atrash S, Makhoul I, Mizell JS, Hutchins L, Mahmoud F. Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better. J Oncol Pharm Pract. 2017 Apr; 23(3):215-219. PMID: 26811403.
      View in: PubMed
    24. Makhoul I, Griffin RJ, Siegel E, Lee J, Dhakal I, Raj V, Jamshidi-Parsian A, Klimberg S, Hutchins LF, Kadlubar S. High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer. Am J Clin Oncol. 2016 06; 39(3):248-54. PMID: 24577164.
      View in: PubMed
    25. Mahmoud F, Shields B, Makhoul I, Hutchins LF, Shalin SC, Tackett AJ. Role of EZH2 histone methyltrasferase in melanoma progression and metastasis. Cancer Biol Ther. 2016 06 02; 17(6):579-91. PMID: 27105109.
      View in: PubMed
    26. Monzavi-Karbassi B, Gentry R, Kaur V, Siegel ER, Jousheghany F, Medarametla S, Fuhrman BJ, Safar AM, Hutchins LF, Kieber-Emmons T. Pre-diagnosis blood glucose and prognosis in women with breast cancer. Cancer Metab. 2016; 4:7. PMID: 27054036.
      View in: PubMed
    27. Coleman HN, Greenfield WW, Stratton SL, Vaughn R, Kieber A, Moerman-Herzog AM, Spencer HJ, Hitt WC, Quick CM, Hutchins LF, Mackintosh SG, Edmondson RD, Erickson SW, Nakagawa M. Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination. Cancer Immunol Immunother. 2016 May; 65(5):563-73. PMID: 26980480.
      View in: PubMed
    28. Klair JS, Girotra M, Hutchins LF, Caradine KD, Aduli F, Garcia-Saenz-de-Sicilia M. Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm. Dig Dis Sci. 2016 07; 61(7):2132-9. PMID: 26846115.
      View in: PubMed
    29. Lencioni A, Hutchins L, Annis S, Chen W, Ermisoglu E, Feng Z, Mack K, Simpson K, Lane C, Topaloglu U. An adverse event capture and management system for cancer studies. BMC Bioinformatics. 2015; 16 Suppl 13:S6. PMID: 26424052.
      View in: PubMed
    30. Greenfield WW, Stratton SL, Myrick RS, Vaughn R, Donnalley LM, Coleman HN, Mercado M, Moerman-Herzog AM, Spencer HJ, Andrews-Collins NR, Hitt WC, Low GM, Manning NA, McKelvey SS, Smith D, Smith MV, Phillips AM, Quick CM, Jeffus SK, Hutchins LF, Nakagawa M. A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3. Oncoimmunology. 2015 Oct; 4(10):e1031439. PMID: 26451301.
      View in: PubMed
    31. Abdallah AO, Herlopian A, Ravilla R, Bansal M, Chandra-Reddy S, Mahmoud F, Ong S, Gokden M, Hutchins L. Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature. J Oncol Pharm Pract. 2016 Jun; 22(3):537-42. PMID: 25712627.
      View in: PubMed
    32. Makhoul I, Klimberg VS, Korourian S, Henry-Tillman RS, Siegel ER, Westbrook KC, Hutchins LF. Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer. Am J Clin Oncol. 2015 Feb; 38(1):74-9. PMID: 23563210.
      View in: PubMed
    33. Makhoul I, Hutchins L, Emanuel PD, Pennisi A, Siegel E, Jousheghany F, Monzavi-Karbassi B, Kieber-Emmons T. Moving a Carbohydrate Mimetic Peptide into the clinic. Hum Vaccin Immunother. 2015; 11(1):37-44. PMID: 25483513.
      View in: PubMed
    34. Pandey S, Nakagawa M, Rosenbaum ER, Arnaoutakis K, Hutchins LF, Makhoul I, Milojkovic N, Cottler-Fox M. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate?) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor. J Clin Apher. 2015 Feb; 30(1):50-4. PMID: 25042026.
      View in: PubMed
    35. Susanibar S, Thrush CR, Khatri N, Hutchins LF. Cancer survivorship training: a pilot study examining the educational gap in primary care medicine residency programs. J Cancer Surviv. 2014 Dec; 8(4):565-70. PMID: 24820428.
      View in: PubMed
    36. Bian J, Xie M, Hogan W, Hutchins L, Topaloglu U, Lane C, Holland J, Wells T. CLARA: an integrated clinical research administration system. J Am Med Inform Assoc. 2014 Oct; 21(e2):e369-73. PMID: 24778201.
      View in: PubMed
    37. Ngo E, Hutchins LF, Gardner JM, Uwaydat SH. Regression of orbital and choroidal metastases from melanoma after treatment with vemurafenib. Can J Ophthalmol. 2014 Apr; 49(2):e49-52. PMID: 24767240.
      View in: PubMed
    38. Dayer LE, Hutchins LF, Johnson JT. Treatment of metastatic melanoma with pazopanib: A report of five patient cases. J Oncol Pharm Pract. 2015 Jun; 21(3):224-31. PMID: 24576945.
      View in: PubMed
    39. Hughes MP, Hardee ME, Cornelius LA, Hutchins LF, Becker JC, Gao L. Merkel Cell Carcinoma: Epidemiology, Target, and Therapy. Curr Dermatol Rep. 2014; 3:46-53. PMID: 24587977.
      View in: PubMed
    40. Starlard-Davenport A, Glover-Collins K, Mahkoul I, Hutchins L, Westbrook K, Korourian S, Enoch K, Preston M, Jackson SN, Klimberg VS, Henry-Tillman R. Race is not a factor in overall survival in patients with triple negative breast cancer: a retrospective review. Springerplus. 2013; 2:516. PMID: 25674397.
      View in: PubMed
    41. Makhoul I, Klimberg VS, Korourian S, Henry-Tillman RS, Siegel ER, Westbrook KC, Hutchins LF. Combined Neoadjuvant Chemotherapy With Bevacizumab Improves Pathologic Complete Response in Patients With Hormone Receptor Negative Operable or Locally Advanced Breast Cancer. Am J Clin Oncol. 2013.
    42. Arnaoutakis K, Graves DA, Hutchins LF, Kieber-Emmons TK. Melanoma - From Early Detection to Treatment. Immunomodulation. 2013.
    43. Arnaoutakis K, Hutchins L, Graves, D, Kieber-Emmons T. Melanoma- From Early Detection to Treatment. Immunomodulatoin. 2013.
    44. Ibrahim S, Topaloglu U, Chen W, Lane C, Mack K, Hogan W, Graves DA, Hutchins L. Simplifying Adverse Event Reporting Using CTCAE v4.0. 2013.
    45. Topaloglu U, Chen W, Ibrahim S, Lane C, Mack K, Hogan W, Annis S, Hutchins L. Managing Adverse Events with a Web-Based Reporting System. 2013.
    46. Javid SH, Unger JM, Gralow JR, Moinpour CM, Wozniak AJ, Goodwin JW, Lara PN, Williams PA, Hutchins LF, Gotay CC, Albain KS. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). Oncologist. 2012; 17(9):1180-90. PMID: 22723506.
      View in: PubMed
    47. Glover-Collins K, Starlard-Davenport A, Makhoul I, Hutchins L, Lee J, Westbrook K, Korourian S, Enoch K, Preston M, Klimberg VS, Henry-Tillman R. Race not a factor in overall survival in patients with triple negative breast cancer: A retropsective review. American Society of Breast Surgeon. 2012.
    48. Enderlin CA, Coleman EA, Cole C, Richards KC, Kennedy RL, Goodwin JA, Hutchins LF, Mack K. Subjective sleep quality, objective sleep characteristics, insomnia symptom severity, and daytime sleepiness in women aged 50 and older with nonmetastatic breast cancer. Oncol Nurs Forum. 2011 Jul; 38(4):E314-25. PMID: 21708527.
      View in: PubMed
    49. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011 Jun 02; 117(22):5827-34. PMID: 21355097.
      View in: PubMed
    50. Kiwan E, Makhoul I, Siegel E, Hutchins L, Maddox AM, Govindarajan, Safar AM. Cetuximab-related first infusion reaction rate in cancer patients. American Society for Clinical Oncology Annual Meeting. 2011.
    51. Topaloglu U, Lane C, Hogan WR, Bian J, Kieber-Emmons T, Hutchins L, Hobbs C. Evaluation of caBIG® tools for the national children’s study. 2011.
    52. Topaloglu U, Konduri SR, Lane C, Hogan WR, Bian J, Hutchins L, Bailey C, Shaughnessy J Jr., Kieber-Emmons T. caArray standalone client for auto importing and uploading array files. caBIG® annual meeting. 2011.
    53. Safar AM, Yacoub A, Hennings L, Beck T, Spencer HJ, Hutchins LF, Eid AA. The study of the immature vessel percentage (IVP) as a potential predictive factor for chemotherapy response in breast cancer: A multicenter study. J Clin Oncol 29:2011. 2011.
    54. Topaloglu U, Jett T, Lane C, Hogan WR, Hicks A, Kieber-Emmons T, Hutchins L. Curating all data elements in a clinical trial with CDEs from caDSR. caBIG® annual meeting. 2011.
    55. Topaloglu U, Lane C, Hogan WR, Bian J, Yip V, Kieber-Emmons T, Hutchins LF. A system for indexing clinical documents for clinical and translational research. 2011.
    56. Topaloglu U, Lane C, Hogan WR, Bian J, Jett T, Yayla I, Feng Z, Kieber-Emmons T, Hutchins L. The caBIG® suite implementation update at the UAMS. caBIG annual meeting. 2011.
    57. Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff M, Hortobagyi GN, Hayes DF, Ambrosone CB. Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res. 2010 Dec 15; 16(24):6169-76. PMID: 21169260.
      View in: PubMed
    58. Krishna K, Yacoub A, Hutchins LF, Kortebein PM. Palmar fasciitis with polyarthritis syndrome in a patient with breast cancer. Clin Rheumatol. 2011 Apr; 30(4):569-72. PMID: 20953809.
      View in: PubMed
    59. Enderlin CA, Coleman EA, Cole C, Richards KC, Hutchins LF, Sherman AC. Sleep across chemotherapy treatment: a growing concern for women older than 50 with breast cancer. Oncol Nurs Forum. 2010 Jul; 37(4):461-A3. PMID: 20591805.
      View in: PubMed
    60. Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hortobagyi GN, Hayes DF, Ambrosone CB. Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Res Treat. 2010 Nov; 124(2):433-9. PMID: 20309628.
      View in: PubMed
    61. Hortobagyi GN, Heim W, Hutchins L, Rivera E, Mason B, Booser DJ, Kirshner J. A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer. 2010 Mar 15; 116(6):1440-5. PMID: 20091835.
      View in: PubMed
    62. Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva DM, Liu PY, Thompson JA, Flaherty LE, Sondak VK. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer. 2010 Jan 15; 116(2):424-31. PMID: 19918923.
      View in: PubMed
    63. Javid SH, Unger JM, Gralow JR, Moinpour CM, Wzniak AJ, Goodwin JW, Lara PN, Williams PA, Hutchins LF, Gotay CC, Albain KS. The influence of older age on physician and patient decision-making regarding enrollment to breast cancer clinical trials. Cancer Research 69(Suppl.):(24). 2009.
    64. O'Day S, Gonzalez R, Lawson D, Weber R, Hutchins L, Anderson C, Haddad J, Kong S, Williams A, Jacobson E. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol. 2009 Nov 10; 27(32):5452-8. PMID: 19826135.
      View in: PubMed
    65. Ambrosone CB, Barlow WE, Reynolds W, Livingston RB, Yeh IT, Choi JY, Davis W, Rae JM, Tang L, Hutchins LR, Ravdin PM, Martino S, Osborne CK, Lyss AP, Hayes DF, Albain KS. Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. J Clin Oncol. 2009; 27(30):4973 - 4979.
    66. Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hayes DF, Ambrosone CB. Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res. 2009 Aug 15; 15(16):5258-66. PMID: 19671875.
      View in: PubMed
    67. Hershman DL, Unger JM, Barlow WE, Hutchins LF, Martino S, Osborne CK, Livingston RB, Albain KS. Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol. 2009 May 01; 27(13):2157-62. PMID: 19307504.
      View in: PubMed
    68. Eid A, Petty M, Hutchins L, Thompson R. "Breaking bad news": standardized patient intervention improves communication skills for hematology-oncology fellows and advanced practice nurses. J Cancer Educ. 2009; 24(2):154-9. PMID: 19431034.
      View in: PubMed
    69. Makhoul I, Klimberg VS, Korourian S, Henry-Tillman RS, Siegel ER, Westbrook KC, Hutchins LF. Bevacizumab combined with chemotherapy significantly improves pathologic complete response in patients with operable or locally advanced breast cancer. 31st Annual San Antonio Breast Cancer Symposium. 2009.
    70. Keshava Prasad H, Nelsen DA, Siegel ER, Raval GG, Rajan S, Hutchins LF. Venous thromboembolism (VTE) and erythropoiesis-stimulating agents (ESAs) in breast cancer: a single tertiary care center experience from the University of Arkansas for Medical Sciences (UAMS). 31st Annual San Antonio Breast Cancer Symposium. 2009.
    71. Wang-Gillam A, Miles DA, Hutchins LF. Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates. Oncologist. 2008 Jul; 13(7):821-7. PMID: 18614589.
      View in: PubMed
    72. Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming GF, Price KN, Thurlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD, SOFT/TEXT/PERCHE Steering Committee, International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. Ann Oncol. 2008; 19(7):1231-41.
    73. Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer CE, Costantino JP, Wolmark N. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol. 2008 Apr 20; 26(12):1965-71. PMID: 18332472.
      View in: PubMed
    74. Ganz PA, Hussey MA, Moinpour CM, Unger JM, Hutchins LF, Dakhil SR, Giguere JK, Goodwin JW, Martino S, Albain KS. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. J Clin Oncol. 2008 Mar 10; 26(8):1223-30. PMID: 18227530.
      View in: PubMed
    75. Eid AA, Safar AM, Hutchins LF, Ray L, Mercado C, Petty M. the fellows presentations evaluation survey (FPES) is a reliable educational method to assess the hematology-oncology fellows (HOFs) presentation skills. J Clin Oncol 26 (May 20 suppl). 2008.
    76. Clark J, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva D, Liu PY, Thompson JA, Sondak VK. Phase II trial of combination thalidomide (thal) plus temozolomide (TMZ [TT]), in patients with metastatic malignant melanoma (MMM): Southwest Oncology Group S0508. J Clin Oncol 26 (May 20 suppl). 2008.
    77. Editor-in Chief:, Hutchins L, Associate Editors: Douglas W. Blayney, MD, Judith S. Ochs, MD, Jennifer E. Schwartz, MD, FRCPC. Achieving Career Success in Oncology. ASCO - American Society of Clinical Oncology. 2008; 308.
    78. Gonzalez R, Lawson DH, Weber RW, Hutchins L, Anderson CM, Williams KN, Kong S, Jacobson E, O'Day SJ. Phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM): Subgroup analysis by prior chemotherapy. J Clin Oncol 26 (May 20 suppl). 2008.
    79. Keshava Prasasd H, Nelsen D, Siegel ER, Raval G, Rajan S, Hutchins LF. Risk of venous thromboembolism (VTE) in breast cancer patients receiving erythropoietin for chemotherapy-induced anemia: A tertiary cancer center experience from the University of Arkansas for Medical Sciences. J Clin Oncol 26 (May 20 suppl). 2008.
    80. Lawson DH, Gonzalez R, Weber RW, Hutchins L, Anderson CM, Williams KN, Kong S, Jacobson E, O'Day SJ. 2-year overall survival (OS) results of a phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM). J Clin Oncol (May 20 suppl). 2008.
    81. Hutchins LF, Moon J, Clark JI, Thompson JA, Lange MK, Flaherty LE, Sondak VK. Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. Cancer. 2007 Nov 15; 110(10):2269-75. PMID: 17932881.
      View in: PubMed
    82. Wang-Gillam A, Siegel E, Mayes D, Hutchins LF, Zhou YH. Anti-tumor effect of doxycycline on glioblastoma cells. J Cancer Molecules. 2007; 5(3(5)):147-153.
    83. Govindarajan R, Young JW, Harless CL, Hutchins LF. Barriers to clinical trials vary according to the type of trial and the institution. J Clin Oncol. 2007 Apr 20; 25(12):1633-4; author reply 1634. PMID: 17443010.
      View in: PubMed
    84. Linden HM, Haskell CM, Green SJ, Osborne CK, Sledge GW, Shapiro CL, Ingle JN, Lew D, Hutchins LF, Livingston RB, Martino S. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). J Clin Oncol. 2007 Feb 20; 25(6):656-61. PMID: 17308269.
      View in: PubMed
    85. Monzavi-Karbassi B, Hennings LJ, Artaud C, Liu T, Jousheghany F, Pashov A, Murali R, Hutchins LF, Kieber-Emmons T. Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma. Vaccine. 2007 Apr 20; 25(16):3022-31. PMID: 17303294.
      View in: PubMed
    86. Hennings L, Artraud C, Jousheghany F, Monzavi-Karbassi B, Hutchins LF, Kieber-Emmons T. Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer. 29th Annual San Antonio Breast Cancer Symposium. 2007.
    87. Wang-Gillam A, Miles DA, Hutchins LF. Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonate therapy. 29th Annual San Antonio Breast Cancer Symposium. 2007.
    88. Eid A, Petty M, Hutchins LF, Thompson AR. Breaking Bad News Standardized Patient Intervention (BBSPI) Improves Hematology-Oncolgy Fellows' and Advanced Practice Nurses: Skills in Breaking Bad News. 2007.
    89. Nair BP, Khalil O, Phooshkooru VR, Hutchins LF. Weight change among breast cancer patients receiving chemotherapy: A retrospective analysis. 2007.
    90. Hershman D, Unger J, Barlow W, Hutchins L, Martino S, Abeloff M, Norton L, Livingston R, Osborne K, Albain K. Treatment quality and outcome of African American vs. European American breast cancer patients: retrospective analysis of southwest oncology group studies S8814/S8897. 29th Annual San Antonio Breast Cancer Symposium. 2007.
    91. Ambrosone CB, Barlow W, Yeh IT, Hayes DF, Davis W, Rae JM, Hutchins LF, Livingston R, Ravdin P, Martino S, Osborne K, Abeloff M, Lyss AP, Albain K. (SWOG) Pharmacogenetics and breast cancer treatment outcomes: results on oxidative stress-related genotypes (MPO, MnSOD) from a southwest oncology group intergroup trial (INT-01012). 29th Annual San Antonio Breast Cancer Symposium. 2007.
    92. Mamounas E, Jeong JH, Wickerman L, Smith R, Geyer C, Ganz P, Land S, Hutchins LF, Eisen A, Ingle J, Constantino J, Wolmark N. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. 29th Annual San Antonio Breast Cancer Symposium. 2007.
    93. Piekarz R, Frye R, Wright J, Figg W, Allen S, Kirschbaum M, Zain J, Hutchins LF, Showe L, Fojo T, Bates SE. Update of the NCI multiinstittutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma. 2007.
    94. O'Day S, Gonzalez R, Lawson D, Weber R, Hutchins LF, Anderson C, MacLeod M, Hurwitz C, Haddad J, Jacobson E. Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase II study of STA-4783 in combination with paclitaxed in patients with metastatic melanoma. 2007.
    95. Gonzalez R, Hutchins L, Nemunaitis J, Atkins M, Schwarzenberger PO. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res. 2006 Dec; 16(6):521-6. PMID: 17119453.
      View in: PubMed
    96. Safar AM, O'Sullivan P, Ray L, Hutchins L, Mehta P. Editorial clubs as a new teaching tool in postgraduate training. J Cancer Educ. 2006; 21(3):163-5. PMID: 17371182.
      View in: PubMed
    97. Unger JM, Coltman CA, Crowley JJ, Hutchins LF, Martino S, Livingston RB, Macdonald JS, Blanke CD, Gandara DR, Crawford ED, Albain KS. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol. 2006 Jan 01; 24(1):141-4. PMID: 16330670.
      View in: PubMed
    98. Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol. 2005 Nov 20; 23(33):8313-21. PMID: 16293862.
      View in: PubMed
    99. Safar AM, Spencer H, Su X, Coffey M, Cooney CA, Ratnasinghe LD, Hutchins LF, Fan CY. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res. 2005 Jun 15; 11(12):4400-5. PMID: 15958624.
      View in: PubMed
    100. Greene GF, Gokden N, Hutchins LF, Williams RC. Metastatic renal cell carcinoma to prostate. Urology. 2005 Jun; 65(6):1227. PMID: 15922439.
      View in: PubMed
    101. Khalil O, Govindarajan R, Safar M, Hutchins L, Mehta P. Clinical trial registration and the ICMJE. JAMA. 2005 Jan 12; 293(2):157; author reply 158. PMID: 15644532.
      View in: PubMed
    102. Shwaiki A, Ratanatharathorn V, Hutchins LF, El-Shihabi S, Linskey M. Textbook of Neuro-Oncology. Mitchel S. Berger and Michael D. Prados, editors. Management of Central Nervous System Metastases from Breast Carcinoma. 2005; p. 404-429.
    103. Pierce LJ, Hutchins LF, Green SR, Lew DL, Gralow JR, Livingston RB, Osborne CK, Albain KS. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol. 2005 Jan 01; 23(1):24-9. PMID: 15545669.
      View in: PubMed
    104. Wong JM, Kyasa MJ, Hutchins L, Collins K. Telomerase RNA deficiency in peripheral blood mononuclear cells in X-linked dyskeratosis congenita. Hum Genet. 2004 Oct; 115(5):448-55. PMID: 15349768.
      View in: PubMed
    105. Huncharek M, Bseiso A, Hutchins L, Warner J. Presentation of malignant pleural mesothelioma with symptomatic brain metastasis: report of a case. Tumori. 2004; 90(4):424 - 427.
    106. Coleman EA, Hutchins L, Goodwin J. An overview of cancer in the older adult. Medsurg Nurs. 2004 Apr; 13(2):75-80, 109; quiz 81. PMID: 15119418.
      View in: PubMed
    107. Kohli M, Zent C, Hutchins LF, Safar M, Dotson P, Mehta P. The academic hematology-oncology firm:a model for postgraduate cancer education. J Cancer Educ. 2004; 19(1):45-9. PMID: 15059755.
      View in: PubMed
    108. Jazieh AR, Kyasa MJ, Hutchins LF. Phase I Clinical Trial of Tamoxifen and Interferon Alpha in the Treatment of Solid Tumors. J Applied Res. 2004; 4(3):464-469.
    109. Hutchins LF, Moon J, Clark J, Thompson J, Yost K, Sondak V. Interferon Alpha-2b and Thalidomide in Previously Treated Patients with Disseminated Malignant Melanoma: SWOG 0026. 2004.
    110. Unger J, Crowley J, Coltman C, Hutchins LF, Martino S, MacDonald J, Gandara D, Crawford E, Livingston R, Albain K. Accrual Patterns of the Southwest Oncology Group (SWOG) by Sex, Race/Ethnicity and Age. 2004.
    111. Unger JM, Hutchins LF, Albain KS. Comprehensive Geriatric Oncology. L Balducci, GH Lyman, WB Ershler, et al, editors. Underrepresentation of elderly patients in cancer clinical trials: Causes and remedial strategies. 2004; p. 259-274.
    112. Kass R, Bellone S, Palmieri M, Can? S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD. Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells. Breast Cancer Res Treat. 2003 Aug; 80(3):275-85. PMID: 14503800.
      View in: PubMed
    113. Kass R, Agha J, Bellone S, Palmieri M, Can? S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD. In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells. J Surg Res. 2003 Jun 15; 112(2):189-97. PMID: 12888337.
      View in: PubMed
    114. Kohli M, Khan MA, Mehta P, Hutchins L. Combined endocrine blockade in premenopausal breast cancer: a superior therapeutic option for adjuvant management? J Clin Oncol. 2003 Jun 15; 21(12):2445. PMID: 12805351.
      View in: PubMed
    115. Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006. PMID: 12637463.
      View in: PubMed
    116. Sweeney C, Ambrosone CB, Joseph L, Stone A, Hutchins LF, Kadlubar FF, Coles BF. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int J Cancer. 2003 Mar 01; 103(6):810-4. PMID: 12516103.
      View in: PubMed
    117. Govindarajan R, Shah RV, Erkman LG, Hutchins LF. Racial differences in the outcome of patients with colorectal carcinoma. Cancer. 2003 Jan 15; 97(2):493-8. PMID: 12518374.
      View in: PubMed
    118. Bedikian A, Gonzalez R, Richards J, Atkins M, Whiman E, Morse M, Amatruda T, Hutchins LF, Thompson J, Galanis E. A Phase II Study of High-Dose Allovectin-7 in Patients with Advanced Metastatic Melanoma. 2003.
    119. Govindarajan R, Safar A, Maddox AM, Hutchins LF. Irinotecan and Thalidomide Prolong Disease Free and Overall Survival in 5FU Refractory Metastatic Colorectal Cancer. 2003.
    120. Chang JC, Kalidas M, Zhou L, Yu S, Cate E, Lowe A, Wilson S, Bedell L, Milan S, Brufsky A, Garino L, Miller J, Hutchins LF, Lee M. Interleukin-2 and Trastuzumab: Preliminary Results in Clinical Response and Natural Killer Cell Expansion in Advanced Her2/Neu Positive Metastatic Breast Cancer Patients. 2003.
    121. Hutchins LF. ASCO Curriculum: Cancer Care in the Older Population. 2003.
    122. Pierce L, Hutchins LF, Green S, Lew D, Gralow J, Livingston R, Osborne K, Albain K. Sequencing of Tamoxifen (TAM) and Radiotherapy (RT) with Breast Conservation (BCT) in Early Stage Breast Cancer. 2003.
    123. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002 May; 8(5):1271-9. PMID: 12006548.
      View in: PubMed
    124. Budd GT, Rankin C, Hutchins LF, Wong L, Petruska PJ, Antman K. Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Southwest Oncology Group. Invest New Drugs. 2002 Feb; 20(1):129-32. PMID: 12003189.
      View in: PubMed
    125. Govindarajan R, Maddox M, Safar A, Gurley J, Hutchins LF. The Efficacy of Thalidomide and Irinotecan in Metastatic Colorectal Carcinoma (Phase II Study). 2002.
    126. Richards J, Thompson J, Atkins M, Hutchins LF, Schuchter L, Gutheil J, Galanis E. A Controlled, Randomized Phase III Trial Comparing the Response to Dacarbazine With and Without Allovectin-7(A) in Patients with Metastatic Melanoma. 2002.
    127. Ganz P, Green S, Hutchins LF, Martino S, Gralow S, Livingston R, Albain K. Late Cardiac Effects of Adjuvant CMF vs. CAF in Women with Node Negative Breast Cancer Treated on SWOG: 8897: Initial results from SWOG 9342. 2002.
    128. Joseph L, Sweeney C, Coles B, Fares M, Hutchins LF, Ambrosone C. Glutathione S-Transferase pi & alpha Enzyme Expression and Patient Survival in Primary Breast Carcinoma. ASCP/CAP. 2001.
    129. Chatterjee M, Lutzky J, Safa M, Sussman J, Bard V, Baral D, Das R, Saha A, Shukla R, Reisfeld R, Hutchins LF, Bhatnagar A, Foon K. Immune and Clinical Comparison of Different Adjuvants Combined with Trigem: An Anti-Idiotype (Anti-Id) Monoclonal Antibody (MAb) Treatments for Stage III Melanoma. 2001.
    130. Safa M, Lutzky J, Chatterjee M, Sussman J, Bard V, Baral D, Das R, Saha A, Shukla R, Reisfeld R, Hutchins LF, Bhatnagar A, Foon K. Trigem Anti-idiotype (Anti-Id) Monoclonal Antibody (MAb) Treatment for Stage III Melanoma: Results of a Multicenter Phase II Trial. 2001.
    131. Govindarajan R, Maddox A, Gray P, Zeitlin A, Hutchins LF. Irinotecan and Thalidomide in Metastatic Colorectal Cancer: Preliminary Results of a Phase II Study. 2001.
    132. Rivera E, Hyzinski M, Hutchins LF, Booser D, Mason B, Hortobagyi G. A Study of UFT+ Leucovorin (L) Given as a Three Times Daily (TID) Regimen in the Treatment of Patients (Pts) with Metastatic Breast Cancer (MBC). 2001.
    133. Gonzalez R, Atkins M, Schwarzenberger P, Lutzky J, Rubin J, Deisseroth A, Blum R, Gutheil J, Hutchins LF. Phase II Trial of HLA-B7 Plasmid DNA/LIPID (Allovectin-7) Immunotherapy in Patients with Metastatic Melanoma (MM) Univ. of Colorado, Denver. Allovectin-7 Phase II Study Group and Vical Incl, San Diego, CA. ASCO. 2000.
    134. Safar AM, Macleod S, Klimberg V, Henry-Tillman R, Fan C, Hutchins LF. Hydralazine-demethylating systemic therapy for breast cancer. 2000.
    135. Hutchins LF, Green S, Ravdin P, Lew D, Martino S, Abeloff M, Lyss A, Henderson C, Allred C, Dakhil S, Pierce I, Goodwin W, Caton J, Rivkin S, Chapman R, Osborne K. Cancer CMF versus CAF +/-Tamoxifen in High-Risk Node-Negative Breast Patients and a Natural History Follow-up Study in Low-risk Node-Negative Patients: U-date of Tamoxifen Results. 22nd Annual Breast Cancer Symposium. 2000.
    136. Mohankrishnan P, Hutchins LF, Nauke S, Sprigg J, Cardwell D, Williamson M, Komoroski R, Jagannathan N. Metabolism of 5-Fluorouracil in Human Liver: An in Vivo FnMR Study. Curr Sci. 1999; 76(5):677-680.
    137. Jazieh A, McIntyre W, Hussain M, Maddox A, Henle K, Nicholas R, Hutchins LF. Phase I Clinical Trial of Tamoxifen and Interferon Alpha in the Treatment of Solid Tumors. 1999.
    138. Foon K, Lutzky J, Baral R, Yannelli J, Hutchins LF, Teitelbaum A, Kashala O, Das R, Garrison J, Reisfeld R, Chatterjee B. Clinical and Immune Responses in Advanced Melanoma Patients Immunized with an Anti-Idiotype Antibody Mimicking Disialonganglioside GD2. 1999.
    139. Margolin KA, Liu PY, Unger JM, Fletcher WS, Flaherty LE, Urba WJ, Hersh EM, Hutchins LE, Sosman JA, Smith JW, Weiss GR, Sondak VK. Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial. J Cancer Res Clin Oncol. 1999; 125(5):292 - 296.
    140. Munn R, Hutchins LF, Garrison J, Sen G, Chakraborty M, Baral R, Romond E, Chatterjee B, Foon K. Immune Responses in Patients with Breast Cancer Treated with an Anti-idiotype Antibody that mimics the Human Milk Fat Globule (HMFG) Antigen. 1998.
    141. Hutchins LF, Green S, Ravdin P, Lew D, Martino S, Abeloff M, Lyss A, Henderson C, Allred C, Dakhil S, Pierce I, Goodwin W, Caton J, Rivkin S, Chapman R, Osborne K. CMF versus CAF With and Without Tamoxifen in High-Risk Node-Negative Breast Cancer Patients and a Natural History Follow-up Study in Low-Risk Node-Negative Patients: First Results of Intergroup Trial INT 0102. 1998.
    142. Miller T, Crowley J, Mira J, Schwartz J, Hutchins LF, Baker L, Natale R, Chase E, Livingston R. A Randomized Trial of Chemotherapy and Radiotherapy for Stage III Non-Small Cell Lung Cancer. Cancer Therapeutics. 1998; 1:229-236.
    143. Hutchins LF, Unger J. Southwest Oncology Group Accrual by Sex, Race and Age, Compared to US Population Rates. J Clin Oncol 17:1596. 1998.
    144. Rankin C, Budd G, Hutchins LF, Antman K. SWOG 9518: Phase II Trial of Continuous Infusion Topotecan in Patients (PTS) with Advanced Soft Tissue Sarcomas (STS). 1998.
    145. Hutchins LF, Unger L, Crowley J, Coltman C, Albain K. Southwest Oncology Group Accrual by Sex, Race and Age, Compared to US Population Rates. 1998.
    146. Govindarajan R, Broadwater R, Maners A, Hutchins LF. Hepatic Arterial infusion (HAI) of cisplatin and adriamycin with whole liver radiation induces sustained remission in unresectable hepatocellular carcinoma (HCC). 1997.
    147. Erwin D, Hutchins LF, Klimberg V. Using Cancer Survivors as Role Models to Inform Breast Cancer Patients about Clinical Trials. 1997.
    148. Albain K, Green S, Lichter A, Hutchins LF, Wood W, Henderson I, Ingle J, O'Sullivan J, Osborne C, Martino S. The Influence of Patient Characteristics, Socioeconomic Factors, Geography, and Systemic Risk on the use of Breast Sparing Treatment in Women Enrolled on Intergroup Adjuvant Breast Cancer Studies. 1996.
    149. Hutchins LF, Fulper-Smith M, Deloney L, Gest T, Roberson P, Berry D. Evaluation of Computer-Based Cancer Education Modules at the Arkansas Cancer Research Center. J Med Educ Technol. 1995; 6(1):4-9.
    150. Hutchins LF, Rector D, Stotts C, Dahlberg S, Coltman C, Albain K. Analysis of Southwest Oncology Group (SWOG) Accrual for Sex Ratios and Associated Socioeconomic Status Factors (SES). 1994.
    151. Lichter A, Green S, Albain K, Hutchins LF, Martino S. Southwest Oncology Group Radiotherapy, Women's Health, and Breast Committees: The Influence of Patient Characteristics, Socioeconomic Factors, Geography, and Systemic Risk on the Use of Breast Sparing Treatment in Adjuvant Breast Cancer Studies. 1994.
    152. Fabian C, Kimler B, McKittrick R, Park C, Lin F, Krishnan L, Jewell W, Osborne K, Martino S, Hutchins LF, Leong L, Green S. Recruitment with High Physiologic dosesof Estradiol Preceding Chemotherapy: Flow Cytometric and Therapeutic Results in Women with Locally Advanced Breast Cancer, A Southwest Oncology Group Study. 1994.
    153. Budd G, Green S, Osborne C, Albain K, Dressier L, Rivkin S, O'Bryan R, Margolin K, Hutchins LF. Recent and Planned Southwest Oncology Group Studies Trials in Operable BreastCancer. Can J Oncol. 1993; 3(Suppl 2):47-53.
    154. Weber B, Arbor A, Vogel C, Jones S, Harvey H, Hutchins LF, Purvis J, Hohneker J. A US Multicenter Phase II Trial of Navelbine in Advanced Breast Cancer. 1993.
    155. Hutchins LF, Nauke S, Sprigg J, Jagannath N, Cardwell D, Tranum B, Komoroski R. In vivo 19-NMR Spectroscopic in Human Liver in Different Combination Regimens. 1992.
    156. Beck J, Hayden K, Hutchins LF, Jagannath S, Barlogie B. Recombinant Human Erythropoietin (rHuEPO) is Effective in Correcting the Anemia of Multiple Myeloma (MM). Proc of ASCO. 1991.
    157. Langston J, Maners A, Klimberg V, Gocio J, Hutchins LF, Lang N, Westbrook K, Broadwater J. Advantages of Papillon Protocol in the Pre-operative Radiation Treatment of Advanced Rectal Carcinoma. Southwestern Surgical Conference. 1991.
    158. Klimberg V, Nwokedi E, Hutchins LF, Pappas A, Lang N, Broadwater J, Read R, Westbrook K. Does Glutamine Facilitate Chemotherapy while Reducing its Toxicity?. 1991; 16-18.
    159. Mohankrishnan P, Hutchins LF, Nauke S, Sprigg J, Jagannath N, Cardwell D, Tranum B, Komoroski RA. Noninvasive Measurement of 5-Fluorouracil Pharmacokinetics in Human Liver using 19-F NMR Spectroscopy. 1990.
    160. Mansouri A, Hutchins LF. Surgical Management of the Elderly. Mark Catlik, Irvin and Schwarzburger, editors. Management of Hemostatic Abnormalities in the Elderly. 1990; p. 139-153.
    161. Bell R, Hough A, Roley J, Hutchins LF, Sanders M. Prognostic Factors in Colorectal Cancer in Young Adults. 1988.
    162. Kletzel M, Becton D, Hutchins LF. Phase I/II trial of High Dose Cytoxan, Continuous Infusion Vincristine, Escalating Doses of BP-16 and TBI with Autologous Bone Marrow Transplants (ABMT). 1988; 90.
    163. Bell R, Hough A, Roley J, Hutchins LF, Sanders M. Prognostic Factors in Colorectal Cancer in Young Adults. American Society of Clinical Pathologists. 1988; 90:493.
    164. Lange T, Garvin K, Jimenez J, Seibert J, Hutchins L, Hough A, Haynes D. Primary malignant bone tumors--a management approach. J Ark Med Soc. 1985; 82(2):115 - 119.
    165. Hutchins LF, Cash D, Lang N, Et. al. Coumarin and Cimetidine as Active Agents in Melanoma and Renal Cell Carcinoma. 1985.
    166. Blachly R, Reid I, Hutchins LF, Et. al. Response and Toxicity of Intraarterial Flosuridine for Hepatic Tumors. 1985.
    Hutchins's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (360) concept(s)
    _
    Co-Authors Expand Description
    See all (50) people
    _
    Similar People Expand Description
    See all (26) people
    _
    Same Department Expand Description
    Search Department